Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy

Antiviral Therapy

Volumn 7, Issue 1, 2002, Pages 43-51

  Ait Khaled, Mounir ^a   Rakik, Abdelrahim ^a   Griffin, Philip ^a   Cutrell, Amy ^b   Fischl, Margaret A ^c   Clumeck, Nathan ^d   Greenberg, Stephen B ^e   Rubio, Rafael ^f   Peters, Barry S ^g   Pulido, Federico ^f   Gould, Jayne ^a   Pearce, Gill ^a   Spreen, William ^b   Tisdale, Margaret ^a   Lafon, Steve ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SENSITIVITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS ISOLATION; VIRUS MUTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GENOTYPE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MUTATION; PHENOTYPE; ZIDOVUDINE;

EID: 0036523770     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, Tisdale M, Parry NR, Reardon JE, Dornsife RE, Averett DR & Krenitsky TA. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrobial Agents and Chemotherapy 1997; 41:1082-1093.
2. Tisdale M, Alnadaf T & Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrobial Agents and Chemotherapy 1997; 41:1094-1098.
3. Faletto MB, Miller WH, Garvey EP, St Clair MH, Daluge SM & Good SS. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrobial Agents and Chemotherapy 1997; 41:1099-1107.
4. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Schlomo Stazewski S, Katlama C, Pearce G & Tisdale M. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and after addition of zidovudine and lamivudine. AIDS 2000; 14:163-171.
5. Lanier R, Ait-Khaled M, Madison S, Hetherington S, Wang B, Dix L & Lafon S. Analysis of possible predictors of response to Abacavir (ABC) in antiretroviral-experienced adults; Comparison of viral genotype, viral phenotype, and patient treatment history. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA January 1999, Abstract 134.
6. Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M & Purdon S on behalf of the CNA3002 European Study Team. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced subjects: results from a randomized, double-blind, trial. AIDS 2000; 14:781-789.
7. Larder BA, Kemp SD & Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.
8. Mellors JW, Bazmi H, Chu CK & Shinazi RF. K65R mutation in HIV-1 reverse transcritptase causes resistance to (-)-b-D-dioxolane-guanosine and reverses AZT resistance. Fifth International workshop on HIV Drug Resistance, Whistler, Canada, 1996, Abstract 7.
9. St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD & Larder BA. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-1559.
10. Harrigan PR, Stone C, Griffin P, Najera I, Bloor S, Kemp S, Tisdale M, Larder B & the CNA2001 Investigation Group. Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (ABC, 1592U89) after Monotherapy and Combination Therapy. Journal of Infectious Diseases 2000; 181:912-920.
11. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F & Brun-Vezinet E Mechanisms of virologic failure, in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Journal of the American Medical Association 1999; 283:205-211.
12. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP & Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. Journal of the American Medical Association 2000, 283:229-234.
13. Fischl M, Greenberg S, Clumeck N, Peters B, Rubio R, Gould J & Boone G. Ziagen (Abacavir, ABC, 1592) Combined with 3TC & ZDV is Highly Effective and Durable Through 48 Weeks in HIV-1 Infected Antiretroviral Therapy Naïve Subjects CNA3003, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, January 1999, Abstract 19.
14. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M & Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993; 365:671-673.
15. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Cloret B, Conway B, Demeter LM, Vella S, Jacobsen DM & Richman DD. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection. Recommendations of an International Aids Society-USA Panel. Journal of the American Medical Association 2000; 283:2417-2426.
16. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B & Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of prorease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrobial Agents and Chemotherapy 1998; 42:269-276.
17. Perrin L. Transmission of drug-resistant HIV. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, January 1999, Abstract S35.
18. Maguire M, Gartland M, Moore S, Hill A, Tisdale M, Harrigan R & Kleim JP. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS 2000 14:1195-1201.
19. Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA & Rubin M. Drug resistance and virologic response in NUCA3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated subjects. AIDS 1996; 10:975-981.
20. Atkinson B, Isaacson J, Knowles M, Mazabel E & Patick AK. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. Journal of Infectious Diseases 2000; 182:420-427.